Abstract:Abstract Cardiac muscle contraction is driven by the molecular motor myosin that uses the energy from ATP hydrolysis to generate a power stroke when interacting with actin filaments, while it is unclear how this mechanism is impaired by mutations in myosin that can lead to heart failure. We have applied a Förster resonance energy transfer (FRET) strategy to investigate structural changes in the lever arm domain of human β-cardiac myosin subfragment 1 (M2β-S1). We exchanged the human ventricular regulatory light chain labeled at a single cysteine (V105C) with Alexa 488 onto M2β-S1, which served as a donor for Cy3ATP bound to the active site. We monitored the FRET signal during the actin-activated product release steps using transient kinetic stopped-flow measurements. We proposed that the fast phase measured with our FRET probes represents the structural change associated with rotation of the lever arm during the power stroke in M2β-S1. Our results demonstrated human cardiac muscle myosin has a slower power stroke compared with fast skeletal muscle myosin and myosin V. Measurements at different temperatures comparing the rate constants of the power stroke and phosphate release revealed that the power stroke occurs before phosphate release, and the two steps are tightly coupled. We speculate that the slower power stroke rate constant in cardiac myosin may correlate with the slower force development and/or unique thin filament activation properties in cardiac muscle. Additionally, we demonstrated that HCM (R723G) and DCM (F764L) associated mutations both reduced actin-activation of the power stroke in M2β-S1. We also demonstrate that both mutations decrease ensemble force development in the loaded in vitro motility assay. Thus, examining the structural kinetics of the power stroke in M2β-S1 has revealed critical mutation-associated defects in the myosin ATPase pathway, suggesting these measurements will be extremely important for establishing structure-based mechanisms of contractile dysfunction. Significance Mutations in human beta-cardiac myosin are known to cause various forms of heart disease, while it is unclear how the mutations lead to contractile dysfunction and pathogenic remodeling of the heart. In this study, we investigated two mutations with opposing phenotypes and examined their impact on ATPase cycle kinetics, structural changes associated with the myosin power stroke, and ability to slide actin filaments in the presence of load. We found that both mutations impair the myosin power stroke and other key kinetic steps as well as the ability to produce ensemble force. Thus, our results provide a structural basis for how mutations disrupt molecular level contractile dysfunction.

Dilated cardiomyopathy myosin mutants have reduced force-generating capacity

Cardiomyopathy Mutations Impact the Power Stroke of Human Cardiac Myosin

Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations

Dilated cardiomyopathy mutation in beta-cardiac myosin enhances actin activation of the power stroke and phosphate release

Hypertrophic cardiomyopathy mutations Y115H and E497D disrupt the folded-back state of human β-cardiac myosin allosterically

Distinct mechanisms drive divergent phenotypes in hypertrophic and dilated cardiomyopathy associated TPM1 variants

Diversity and Similarity of Motor Function and Cross-Bridge Kinetics in Papillary Muscles of Transgenic Mice Carrying Myosin Regulatory Light Chain Mutations D166V and R58Q.

The D75N and P161S Mutations in the C0-C2 Fragment of cMyBP-C Associated with Hypertrophic Cardiomyopathy Disturb the Thin Filament Activation, Nucleotide Exchange in Myosin, and Actin–Myosin Interaction

Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain

Mechanical Dysfunction Of The Sarcomere Induced By A Pathogenic Mutation In Troponin T Drives Cellular Adaptation

An Cardiomyocyte Reveals the Impact of Changes in CAMKII Signalling on Cardiomyocyte Contraction Kinetics in Hypertrophic Cardiomyopathy

Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice

Converter domain mutations in myosin alter structural kinetics and motor function

Mechanical dysfunction induced by a hypertrophic cardiomyopathy mutation is the primary driver of cellular adaptation

Hypertrophic cardiomyopathy associated E22K mutation in myosin regulatory light chain decreases calcium‐activated tension and stiffness and reduces myofilament Ca <sup>2+</sup> sensitivity

In silico and in vitro models reveal the molecular mechanisms of hypocontractility caused by TPM1 M8R

A Failure to Communicate: MYOSIN RESIDUES INVOLVED IN HYPERTROPHIC CARDIOMYOPATHY AFFECT INTER-DOMAIN INTERACTION

An In Silico Cardiomyocyte Reveals the Impact of Changes in CaMKII Signalling on Cardiomyocyte Contraction Kinetics in Hypertrophic Cardiomyopathy

Dilated cardiomyopathy-associated skeletal muscle actin (ACTA1) mutation R256H disrupts actin structure and function and causes cardiomyocyte hypocontractility

Hypertrophic cardiomyopathy associated E22K mutation in myosin regulatory light chain decreases calcium-activated tension and stiffness and reduces myofilament Ca<SUP>2+</SUP> sensitivity

Myosin Rod Hypophosphorylation and CB Kinetics in Papillary Muscles from a TnC-A8V KI Mouse Model.